Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Mixed quarterly results as Union Pacific and Western Union meet or beat expectations, while Euronet and Eastern Bank miss, and Amalgamated Financial delivers solid organic growth.
Prolonged U.S. government shutdown exacerbates hardships, as negotiations intensify and lawmakers face pressure to resolve the impasse.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Mixed quarterly results as Union Pacific and Western Union meet or beat expectations, while Euronet and Eastern Bank miss, and Amalgamated Financial delivers solid organic growth.
Prolonged U.S. government shutdown exacerbates hardships, as negotiations intensify and lawmakers face pressure to resolve the impasse.